Abstract:Aim: To observe the therapeutic efficacy and prognostic factors that influence survival rates in non-small cell lung cancer (NSCLC) patients with multiple brain metastases (BMs), (more than three and less than ten).Methods: Retrospective analyses were conducted on the clinical data of 209 NSCLC patients with multiple BMs and were admitted to our hospital between March 2007 and November 2012. All BM patients received whole-brain radiotherapy. Two hundred patients received combined chemotherapy during the treatment process; 99 received targeted drug therapy; and nine got only symptomatic and supportive treatment. Survival time was defined as the period from the start of BM therapy to the patient's death or end of the follow-up period. The Kaplan-Meier method was used to calculate the median survival time, and the 6-month, 1-, and 2-year cumulative survival rates, as well as to plot the survival curves. The patients' cultural background included their socioeconomic status, level of education, their understanding of the disease, and the degree of care and support they received from their family members. Log-rank test was employed to test the differences in the survival rates between the subgroups. Cox multivariate regression analyses were used to analyze the various factors influencing the prognoses of NSCLC with multiple BMs.Results: The follow-up duration was between 1 and 87 months. The median survival time for all BM patients was 12.1 months (95% confidence interval 9.37-14.83). The 6-month, 1-, and 2-year cumulative survival rates were 80%, 50.2%, and 10.7%, respectively. Univariate analyses revealed that the independent factors influencing survival prognoses included Karnofsky Performance Status score, control of the primary lung tumor, interval between the confirmed diagnoses of lung cancer and BM, presence of extracranial metastasis, number of chemotherapy cycles undergone, Graded Prognostic Assessment class, administration of combined targeted drug therapy, the pathological type, and the cultural backgrounds of the patients. Multivariate analyses indicated that the number of chemotherapy cycles, administration of combined drug therapy, and patients' cultural background were key independent factors influencing survival prognoses.Conclusion: Active treatment of NSCLC with multiple BMs was beneficial, and the patients' cultural background had a strong influence on survival prognoses. Chemotherapy combined with targeted drug therapy could increase the patients' median and overall survival rates. The number of chemotherapy cycles undergone, administration of combined targeted drug therapy, and the cultural backgrounds of the patients had significant effects on the patients' survival prognoses.

Multidrug Resistance Protein and Topoisomerase 2 Alpha Expression in Non-Small Cell Lung Cancer Are Related with Brain Metastasis Postoperatively.

Expressions and Significances of Topoisomeraseⅱ and Multidrug Resistance-Associated Protein in Human Esophageal Squamous Cell Carcinoma

[Clinical Significance of Multidrug Resistance-Associated Protein(mrp) Gene Expression in Non-Small Cell Lung Cancer].

Expression and clinical significance of multidrug resistance associated protein-1 and DNA topoisomerase-Ⅱ

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference Between Mrna and Protein Expression in Predicting Prognosis of Breast Cancer Patients

Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

[Expression of Multiple Drug Resistance-Associated Proteins in Non-Small Cell Lung Cancer Tissues and Its Clinical Significance].

Prognostic Significance of TOP2A in Non-Small Cell Lung Cancer Revealed by Bioinformatic Analysis

Analyses of Prognostic Factors in Cases of Non-Small Cell Lung Cancer with Multiple Brain Metastases

Expression and Prognostic Significance of Multidrug Resistance Associated Protein (MRP) Gene in Non-Small Cell Lung Cancer by in Site Hybridization

Prognostic value of MRP , LRP and Pgp in patients with non-small cell lung cancer

Mining Expression and Prognosis of Topoisomerase Isoforms in Non-Small-cell Lung Cancer by Using Oncomine and Kaplan–Meier Plotter

Expression and potential molecular mechanism of TOP2A in metastasis of non-small cell lung cancer

Clinical significance of detecting MRP in 110 patients with lung cancer

The role of TOP2A in immunotherapy and vasculogenic mimicry in non-small cell lung cancer and its potential mechanism

The Prognostic Significance of Topoisomerase II Alpha Protein in Early Stage Luminal Breast Cancer

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

Positive Expression of P53, C-Erbb2 and MRP Proteins is Correlated with Survival Rates of NSCLC Patients.

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

[Expression of Topoisomerase IIalpha in Nasopharyngeal Carcinoma and Its Clinical Significance].

Clinical Relevance of the Multidrug Resistance‑associated Protein 1 Gene in Non‑small Cell Lung Cancer: A Systematic Review and Meta‑analysis.